Diagnostic markers based on a computational model of lipoprotein metabolism

Journal of Clinical Bioinformatics

Volumn 1, Issue 1, 2011, Pages

  Van Schalkwijk, Daniël B ^a,b,c   van Ommen, Ben ^a   Freidig, Andreas P ^d   van der Greef, Jan ^a,b   de Graaf, Albert A ^a  

^a TNO   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c NETHERLANDS BIOINFORMATICS CENTRE   (Netherlands)

^d Amsterdam Molecular Therapeutics (AMT) BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84862189675     PISSN: None     EISSN: 20439113     Source Type: Journal    
DOI: 10.1186/2043-9113-1-29     Document Type: Article

References (32)

1. Cromwell WC, Otvos JD. Low-density lipoprotein particle number and risk for cardiovascular disease. Curr Atheroscl Rep 2004, 6:381-387.
2. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239. 10.1161/01.CIR.0000133317.49796.0E, 15249516.
3. Otvos JD, Jeyarajah EJ, Bennett DW, Krauss RM. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem 1992, 38:1632-1638.
4. Usui S, Hara Y, Hosaki S, Okazaki M. A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC. J Lipid Res 2002, 43:805-814.
5. Caulfield MP, Li S, Lee G, Blanche PJ, Salameh WA, Benner WH, Reitz RE, Krauss RM. Direct Determination of Lipoprotein Particle Sizes and Concentrations by Ion Mobility Analysis. Clin Chem 2008, 54:1307-1316. 10.1373/clinchem.2007.100586, 18515257.
6. Caulfield MP, Li S, Lee G, Blanche PA, Salameh WA, Benner WH, Reitz RE, Krauss RM. In Reply. Clin Chem 2008, 54:2088-2089.
7. Rambaldi DC, Zattoni A, Casolari S, Reschiglian P, Roessner D, Johann C. An Analytical Method for Size and Shape Characterization of Blood Lipoproteins. Clin Chem 2007, 53:2026-2029. 10.1373/clinchem.2007.091942, 18035594.
8. Olivecrona T, Hultin M, Bergö M, Olivecrona G. Lipoprotein lipase: regulation and role in lipoprotein metabolism. Proceedings of the Nutrition Society 1997, 56:723-729. 10.1079/PNS19970072, 9264122.
9. Olivecrona T, Bengtsson-Olivecrona G. Lipoprotein lipase and hepatic lipase. Current Opinion in Lipidology 1993, 4:187-196.
10. Demant T, Carlson LA, Holmquist L, Karpe F, Nilsson-Ehle P, Packard CJ, Shepherd J. Lipoprotein metabolism in hepatic lipase deficiency: studies on the turnover of apolipoprotein B and on the effect of hepatic lipase on high density lipoprotein. J Lipid Res 1988, 29:1603-1611.
11. Frayn KN. Metabolic Regulation, A Human Perspective 2003, Oxford: Blackwell Science Ltd.
12. Parhofer KG, Barrett PH. What we have learned about VLDL and LDL metabolism from human kinetic studies. J Lipid Res 2006, 47:1620-1630. 10.1194/jlr.R600013-JLR200, 16720894.
13. van Schalkwijk DB, de Graaf AA, van Ommen B, van Bochove K, Rensen PCN, Havekes LM, van de Pas NCA, Hoefsloot HCJ, van der Greef J, Freidig AP. Improved cholesterol phenotype analysis by a model relating lipoprotein life cycle processes to particle size. J Lipid Res 2009, 50:2398-2411. 10.1194/jlr.M800354-JLR200, 2781312, 19515990.
14. van Schalkwijk DB, van Bochove K, van Ommen B, Freidig AP, van Someren EP, van der Greef J, de Graaf AA. Developing computational model-based diagnostics to analyse clinical chemistry data. Brief Bioinform 2010, 11:403-416. 10.1093/bib/bbp071, 20056728.
15. Packard CJ, Gaw A, Demant T, Shepherd J. Development and application of a multicompartmental model to study very low density lipoprotein subfraction metabolism. J Lipid Res 1995, 36:172-187.
16. Demant T, Gaw A, Watts GF, Durrington P, Buckley B, Imrie CW, Wilson C, Packard CJ, Shepherd J. Metabolism of apoB-100-containing lipoproteins in familial hyperchylomicronemia. J Lipid Res 1993, 34:147-156.
17. Demant T, Bedford D, Packard CJ, Shepherd J. Influence of apolipoprotein E polymorphism on apolipoprotein B-100 metabolism in normolipemic subjects. J Clin Invest 1991, 88:1490-1501. 10.1172/JCI115459, 295655, 1939641.
18. Packard CJ, Demant T, Stewart JP, Bedford D, Caslake MJ, Schwertfeger G, Bedynek A, Shepherd J, Seidel D. Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions. J Lipid Res 2000, 41:305-318.
19. James RW, Martin B, Pometta D, Fruchart JC, Duriez P, Puchois P, Farriaux JP, Tacquet A, Demant T, Clegg RJ, et al. Apolipoprotein B metabolism in homozygous familial hypercholesterolemia. J Lipid Res 1989, 30:159-169.
20. Demant T, Packard CJ, Demmelmair H, Stewart P, Bedynek A, Bedford D, Seidel D, Shepherd J. Sensitive methods to study human apolipoprotein B metabolism using stable isotope-labeled amino acids. Am J Physiol 1996, 270:E1022-E1036.
21. Demant T, Mathes C, Gutlich K, Bedynek A, Steinhauer HB, Bosch T, Packard CJ, Warwick GL. A simultaneous study of the metabolism of apolipoprotein B and albumin in nephrotic patients. Kidney Int 1998, 54:2064-2080. 10.1046/j.1523-1755.1998.00204.x, 9853272.
22. Lundahl B, Skoglund-Andersson C, Caslake M, Bedford D, Stewart P, Hamsten A, Packard CJ, Karpe F. Microsomal triglyceride transfer protein -493T variant reduces IDL plus LDL apoB production and the plasma concentration of large LDL particles. Am J Physiol Endocrinol Metab 2006, 290:E739-E745.
23. Schmitz M, Michl GM, Walli R, Bogner J, Bedynek A, Seidel D, Goebel FD, Demant T. Alterations of apolipoprotein B metabolism in HIV-infected patients with antiretroviral combination therapy. J Acquir Immune Defic Syndr 2001, 26:225-235. 10.1097/00126334-200103010-00004, 11242195.
24. Bilz S, Wagner S, Schmitz M, Bedynek A, Keller U, Demant T. Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia. J Lipid Res 2004, 45:174-185.
25. Forster LF, Stewart G, Bedford D, Stewart JP, Rogers E, Shepherd J, Packard CJ, Caslake MJ. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates. Atherosclerosis 2002, 164:129-145. 10.1016/S0021-9150(02)00052-7, 12119202.
26. Packard CJ, Shepherd J, Lindsay GM, Gaw A, Taskinen MR. Thyroid replacement therapy and its influence on postheparin plasma lipases and apolipoprotein-B metabolism in hypothyroidism. J Clin Endocrinol Metab 1993, 76:1209-1216. 10.1210/jc.76.5.1209, 8496312.
27. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990, 82:495-506. 10.1161/01.CIR.82.2.495, 2372896.
28. Obuchowski NA. ROC analysis. Am J Roentgenol 2005, 184:364-372.
29. Gaffney D, Forster L, Caslake MJ, Bedford D, Stewart JP, Stewart G, Wieringa G, Dominiczak M, Miller JP, Packard CJ. Comparison of apolipoprotein B metabolism in familial defective apolipoprotein B and heterogeneous familial hypercholesterolemia. Atherosclerosis 2002, 162:33-43. 10.1016/S0021-9150(01)00679-7, 11947895.
30. Nierman MC, Prinsen BHCM, Rip J, Veldman RJ, Kuivenhoven JA, Kastelein JJP, de Sain-van der Velden M, Stroes ESG. Enhanced Conversion of Triglyceride-Rich Lipoproteins and Increased Low-Density Lipoprotein Removal in LPLS447X Carriers. Arterioscler Thromb Vasc Biol 2005, 25:2410-2415. 10.1161/01.ATV.0000188506.79946.ce, 16195478.
31. Ruel IL, Couture P, Cohn JS, Lamarche B. Plasma metabolism of apoB-containing lipoproteins in patients with hepatic lipase deficiency. Atherosclerosis 2005, 180:355-366. 10.1016/j.atherosclerosis.2004.12.014, 15910863.
32. Adiels M. Compartmental Models of Lipoprotein Kinetics. PhD Thesis 2004, PhD Thesis, Chalmers University of Technology, Göteborg, Sweden.